Inhibikase Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IKT research report →
About the company
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration.
- CEO
- Mark T. Iwicki
- IPO
- 2020
- Employees
- 35
- HQ
- Wilmington, DE, US
Price Chart
- Market Cap
- $262.74M
- P/E
- -3.69
- P/S
- 0.00
- P/B
- 1.17
- EV/EBITDA
- -3.95
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -41.31%
- ROIC
- -33.17%
- Revenue
- $0 · 0.00%
- Net Income
- $-48,259,189 · -75.36%
- EPS
- $-0.49 · 57.76%
- Op Income
- $-51,974,283
- FCF YoY
- -45.11%
- 52W High
- $2.26
- 52W Low
- $1.33
- 50D MA
- $1.81
- 200D MA
- $1.71
- Beta
- 0.94
- Avg Volume
- 847.47K
Get TickerSpark's AI analysis on IKT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 26, 26 | BERMAN DENNIS N | other | 155,000 |
| Jun 26, 26 | Canner David | other | 155,000 |
| Jun 26, 26 | Kush Arvind | other | 155,000 |
| Jun 26, 26 | Bellini Roberto | other | 155,000 |
| Jun 26, 26 | Aurentz Vincent | other | 155,000 |
| Jun 26, 26 | Munshi Amit | other | 155,000 |
| Feb 21, 26 | Aurentz Vincent | sell | 255,299 |
| Feb 21, 26 | Cabell Christopher | sell | 338,282 |
| Feb 21, 26 | Munshi Amit | sell | 19,089 |
| Jan 5, 26 | Iwicki Mark T | other | 4,982,706 |
Our IKT coverage
Recent articles, reports, and earnings notes.
No research on IKT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IKT report →Similar companies
Peers in the same neighborhood.